Group 5D: Kidney Cancer

Friday, June 10
2:00 pm – 3:30 pm Eastern Time (US/New York)

Mentor: Deb Maskens

Deb Maskens is a long-time kidney cancer patient and patient advocate. Along with another patient, she Co-Founded Kidney Cancer Canada in 2016 and played an active leadership role for 10 years. During this time she focused on advocacy, health technology assessment, patient support and navigation.

Deb currently volunteers for several kidney cancer patient organizations including the Kidney Cancer Association in the USA. In recent years she served as a Patient Advocate on the NCI Renal Task Force and as Co-Lead of the Canadian CanCertainty Coalition campaign of 35 cancer organizations advocating for health policy change ( Previous roles include 10 years as a Founding Member and Vice Chair of the International Kidney Cancer Coalition ( based in Amsterdam.

In 2016, Deb was awarded the Canadian Governor General’s Meritorious Service Medal, Canada’s highest award for her dedication and professionalism in patient advocacy and volunteer service. Deb is a frequent speaker at national and international cancer meetings where she provides the patient voice perspective, along with sound advocacy knowledge and experience.

Twitter: @DebMaskens

Scientist: Chung-Han Lee, M.D., Ph.D.

Chung-Han Lee, M.D., Ph.D. is a medical oncologist that specializes in the care of people with genitourinary malignancies, including kidney, bladder, and prostate cancer. As part of a multidisciplinary team of surgeons, radiation oncologists, pathologists, and medical oncologists, he strives to provide the optimal care for each patient’s unique situation. In addition to standard-of-care options, our team enables patients to participate in promising and innovative clinical trials as additional options for clinical care.

His primary research interests include the development of novel agents and treatment strategies for genitourinary malignancies, especially kidney cancer. As a physician-scientist, he is also an active member of the Translational Kidney Cancer Research Program at MSK and closely collaborates with translational and basic science researchers in MSK’s Human Oncology and Pathogenesis Program. His laboratory research focuses on identifying novel pathways that may be involved in pathogenesis and developing better biomarkers to predict response to therapy.

Twitter: @chunghanlee3